3BP 227

Drug Profile

3BP 227

Alternative Names: 3BP227

Latest Information Update: 10 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator 3B Pharmaceuticals
  • Class Antineoplastics; Peptide diagnostics; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Neurotensin type 1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase 0 Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 10 Sep 2015 3B Pharmaceuticals plans a phase I trial for Small cell lung cancer and Pancreatic cancer (Diagnosis) in Germany
  • 03 Feb 2015 Phase-0 for Pancreatic cancer (Diagnosis) in Germany (unspecified route) before February 2015
  • 03 Feb 2015 Phase-0 for Pancreatic cancer in Germany (unspecified route) before February 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top